Lucid Diagnostics gets Nasdaq notice: LUCD bid under $1 for 30 days, 180 days to cure

Lucid Diagnostics Inc.

Nasdaq notified Lucid on Oct 12, 2026 that LUCD's closing bid price was below $1/share for 30 consecutive business days through Oct 9, 2026, per Listing Rule 5550(a)(2).
Company has until April 12, 2027 (180 calendar days) to regain compliance, requiring a closing bid of at least $1 for a minimum of ten consecutive business days.
If not cured, Lucid may qualify for an additional 180-day period; otherwise Nasdaq will notify the company of delisting after the initial period ends.
LUCD continues to trade uninterrupted on the Nasdaq Capital Market; company says it will consider all available options to regain compliance.
Filing signed Oct 16, 2026 by CFO Dennis McGrath; no other exhibits beyond the XBRL cover page.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.